CN112119092A - 改进的拮抗性抗人cd40单克隆抗体 - Google Patents

改进的拮抗性抗人cd40单克隆抗体 Download PDF

Info

Publication number
CN112119092A
CN112119092A CN201980025343.4A CN201980025343A CN112119092A CN 112119092 A CN112119092 A CN 112119092A CN 201980025343 A CN201980025343 A CN 201980025343A CN 112119092 A CN112119092 A CN 112119092A
Authority
CN
China
Prior art keywords
antibody
cells
antigen
sequence
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980025343.4A
Other languages
English (en)
Chinese (zh)
Inventor
安东·埃格伯特·彼得·阿当
马克·德波尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diabetes Free Co
Original Assignee
Diabetes Free Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diabetes Free Co filed Critical Diabetes Free Co
Publication of CN112119092A publication Critical patent/CN112119092A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980025343.4A 2018-02-12 2019-02-11 改进的拮抗性抗人cd40单克隆抗体 Pending CN112119092A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18156288 2018-02-12
EP18156288.5 2018-02-12
PCT/NL2019/050086 WO2019156565A1 (en) 2018-02-12 2019-02-11 Improved antagonistic anti-human cd40 monoclonal antibodies

Publications (1)

Publication Number Publication Date
CN112119092A true CN112119092A (zh) 2020-12-22

Family

ID=61192786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980025343.4A Pending CN112119092A (zh) 2018-02-12 2019-02-11 改进的拮抗性抗人cd40单克隆抗体

Country Status (8)

Country Link
US (2) US11396552B2 (https=)
EP (1) EP3752532A1 (https=)
JP (2) JP2021513367A (https=)
KR (1) KR20200141986A (https=)
CN (1) CN112119092A (https=)
AU (1) AU2019217207B2 (https=)
CA (1) CA3090322A1 (https=)
WO (1) WO2019156565A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
JP2021513367A (ja) * 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
CN115605594A (zh) * 2020-06-02 2023-01-13 帝人制药株式会社（Jp） 抗igf-1受体人源化抗体
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2025122817A1 (en) * 2023-12-06 2025-06-12 The General Hospital Corporation Antagonistic cd40 antibodies
KR20250116195A (ko) * 2024-01-24 2025-08-01 서울대학교산학협력단 Cd40에 특이적으로 결합하는 항체 및 이의 용도
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938045A (zh) * 2003-11-04 2007-03-28 希龙公司 治疗自身免疫和炎性疾病以及器官移植排异的拮抗性抗－cd40抗体的应用
US20080085531A1 (en) * 2006-05-09 2008-04-10 Pangenetics B.V. Antagonistic anti-human CD40 monoclonal antibody
CN101426817A (zh) * 2006-04-21 2009-05-06 诺华有限公司 拮抗性抗-cd4o抗体药物组合物
US20110243932A1 (en) * 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies
US20160347850A1 (en) * 2015-05-29 2016-12-01 Abbvie Inc. Anti-cd40 antibodies and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1178786B (it) 1984-12-21 1987-09-16 Assorenti Analoghi retro-inverso parzialmente modificati della neurotensina
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU649217B2 (en) 1988-11-18 1994-05-19 Regents Of The University Of California, The Method for site-specifically incorporating unnatural amino acids into proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
HUT71860A (en) 1992-08-27 1996-02-28 Deakin Res Ltd Retro-, inverso-, and retro-inverso synthetic peptide analogues
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6339069B1 (en) 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6103489A (en) 1997-03-21 2000-08-15 University Of Hawaii Cell-free protein synthesis system with protein translocation and processing
CA2303268A1 (en) 1997-06-13 1998-12-17 Scott Walsh Therapeutic nanospheres
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
FR2840307B1 (fr) 2002-05-30 2006-07-07 Centre Nat Rech Scient Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
WO2005006949A2 (en) 2003-07-07 2005-01-27 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7659252B2 (en) 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
US20070237826A1 (en) 2006-04-05 2007-10-11 Rao Kollipara K Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
EP2067785A1 (en) 2007-12-03 2009-06-10 Fresenius Medical Care Deutschland GmbH Human CD154-binding synthetic peptide and uses thereof
US8734786B2 (en) 2009-09-16 2014-05-27 Northwestern University Use of ECDI-fixed cell tolerance as a method for preventing allograft rejection
WO2011069037A2 (en) 2009-12-03 2011-06-09 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
ES2957957T3 (es) 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
CA2832281C (en) 2011-04-04 2019-11-05 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
WO2012145632A1 (en) 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
KR101329411B1 (ko) 2012-05-31 2013-11-14 주식회사 엘지생활건강 피부투과성 펩타이드
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
US20180172683A1 (en) 2015-06-22 2018-06-21 University Of Southern California Methods for analyzing the interaction between a target protein and a ligand
KR101810778B1 (ko) 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
JP2021513367A (ja) * 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938045A (zh) * 2003-11-04 2007-03-28 希龙公司 治疗自身免疫和炎性疾病以及器官移植排异的拮抗性抗－cd40抗体的应用
CN101426817A (zh) * 2006-04-21 2009-05-06 诺华有限公司 拮抗性抗-cd4o抗体药物组合物
US20080085531A1 (en) * 2006-05-09 2008-04-10 Pangenetics B.V. Antagonistic anti-human CD40 monoclonal antibody
US20110243932A1 (en) * 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies
US20160347850A1 (en) * 2015-05-29 2016-12-01 Abbvie Inc. Anti-cd40 antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROBERT H VONDERHEIDE等: "CD40 immunotherapy for pancreatic cancer", 《CANCER IMMUNOL IMMUNOTHER》, vol. 62, no. 5, pages 949 - 954, XP002794846, DOI: 10.1007/s00262-013-1427-5 *
张界等: "CD40单克隆抗体的制备、筛选及功能鉴定", 《现代免疫学》, vol. 37, no. 05, pages 353 - 359 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
WO2022247905A1 (zh) * 2021-05-26 2022-12-01 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途

Also Published As

Publication number Publication date
US11396552B2 (en) 2022-07-26
KR20200141986A (ko) 2020-12-21
AU2019217207A1 (en) 2020-08-27
US20230059094A1 (en) 2023-02-23
AU2019217207B2 (en) 2025-12-18
JP2024024118A (ja) 2024-02-21
CA3090322A1 (en) 2019-08-15
US20210101991A1 (en) 2021-04-08
JP2021513367A (ja) 2021-05-27
WO2019156565A1 (en) 2019-08-15
EP3752532A1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
US11396552B2 (en) Antagonistic anti-human CD40 monoclonal antibodies
CN107810198B (zh) 抗cd40抗体及其用途
AU2019202447B2 (en) Binding molecules specific for il-21 and uses thereof
CN113396162A (zh) 抗IL-7Rα亚基的抗体及其用途
EA039946B1 (ru) Антитела-антагонисты к интерферону альфа и интерферону омега
CN121057750A (zh) 结合ox40l的抗体和使用方法
JP2012520329A (ja) 抗腫瘍活性を有するヒト化抗体
US20250270328A1 (en) Klrb1 binding agents and methods of use thereof
RU2804456C1 (ru) Связывающие молекулы, специфичные к ил-21, и области их применения
TW202607021A (zh) 結合ｔｓｌｐ之抗體及使用方法
US20210095011A1 (en) Improved anti-fibronectin eda antibodies
HK40130326A (zh) 结合白介素4受体α的抗体和使用方法
IL323599A (en) Anti-IL-25 antibodies and methods of using them
BR112016029734B1 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno deste e uso do mesmo, composição farmacêutica e método para detecção de níveis de expressão de il-21 em uma amostra
NZ725735B2 (en) Binding molecules specific for il-21 and uses thereof
HK1230976A1 (en) Binding molecules specific for il-21 and uses thereof
HK1230976B (en) Binding molecules specific for il-21 and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination